EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has scheduled its third quarter 2024 financial results release for November 7, 2024, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has scheduled its third quarter 2024 financial results release for November 7, 2024, before market open. The company will host a conference call and webcast at 8:30 AM EDT on the same day. CEO Ryan Rhodes, CFO Ken Mobeck, and CAO François Dietsch will lead the discussion. The conference call will be accessible via domestic (1-800-445-7795) and international (1-785-424-1699) dial-in numbers using passcode EDAP.
Details
News Market Reaction – EDAP
The recorded move for EDAP in the trading session of this news was +4.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT
LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7th, 2024.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
Date: Thursday, November 7th
Time: 8:30 am EDT
Domestic: 1-800-445-7795
International: 1-785-424-1699
Passcode: EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691338&tp_key=a13da04d10
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.